Xintela AB
556780-3480ActiveDeveloping stem cell and targeted cancer therapies for unmet needs.
Publicly Traded Biopharmaceutical Companyxintela.se
Yleiskatsaus
- 10–19
- Työntekijät
- 2.5–5milj SEK
- Liikevaihto
- 2009
- Perustettu
Avainpäättäjät
Lars Hedbys
Board member
Evy Lundgren-Åkerlund
Chief Executive Officer
Maarten de Château
Board member
Gunnar Telhammar
CFO
+9 lisää yhteystietoja Funnelfeedrissä
Kuvaus
Xintela is a Swedish biopharmaceutical company focused on developing innovative treatments in stem cell therapy and targeted cancer therapy. The organization aims to address significant unmet medical needs in areas like osteoarthritis and aggressive cancers. Its core stem cell product, XSTEM®, is be...